- [Resource Hub](/) - [Application Note](/?resource-type=application-note#library) - CAR-T Expansion Monitoring: Consolidated Cell Characterization Using Moxi GO II # CAR-T Expansion Monitoring: Consolidated Cell Characterization Using Moxi GO II CAR-T expansion QC has long leaned on two separate core-lab instruments — a Coulter counter for counting and sizing, and a multi-parameter flow cytometer for viability and immunophenotyping — whose 3–6 hour turnaround can arrive after the intervention window has closed; this University of Pennsylvania study (Pajarillo et al., Cytotherapy 2024) shows the Moxi GO II consolidating both into a single 15-second, at-bench measurement. Working at the University of Pennsylvania Center for Cellular Immunotherapies (Ruella Lab), the authors benchmarked the Moxi GO II — a compact, battery-powered instrument that pairs Coulter-principle volumetric sizing with 2-color fluorescence detection — against the gold-standard two-instrument workflow (a Beckman Coulter Multisizer and a BD LSRFortessa) across routine CAR-T expansion assays. From 60 µL of stained sample, a single 15-second test returns cell count, size, viability, and CD4/CD8 and CAR19 phenotyping, matching the reference instruments for viability (r² = 0.97), CD4+ T cell identification (r² = 0.997), and CAR19 transduction efficiency (r² = 0.90). The note also states plainly where the instrument fits — the routine 2-color checkpoints that make up most of an expansion campaign — and where high-parameter flow cytometry is still the right tool. Read or download to see: - Two instruments consolidated into one 15-second test — the Moxi GO II combines Coulter-principle counting and sizing with 2-color fluorescence viability and immunophenotyping in a single at-bench measurement from 60 µL of sample, replacing the standard workflow of a separate Coulter counter plus a multi-parameter flow cytometer. - The 3–6 hour core-lab turnaround eliminated — routine expansion checkpoints no longer wait on dual core-instrument scheduling, sample transport, and cytometrist availability; actionable QC data arrives at the bench at the moment expansion decisions are being made. - Viability matched the flow cytometer at r² = 0.97 — the Moxi GO II's Coulter-based viability assessment correlated at r² = 0.97 (P [Download the application note PDF · 1.5 MB · 8 pages](https://cdn.sanity.io/files/o7963fe7/production/b77fb08ee7a41406beb754fca6dee60f47c96f48.pdf) Your browser doesn’t support embedded PDFs. [Download the application note](https://cdn.sanity.io/files/o7963fe7/production/b77fb08ee7a41406beb754fca6dee60f47c96f48.pdf) to view it. For research use only. [Back to all resources](/#library) ## Similar resources [App Note](https://precisioncellsystems.com/wp-content/uploads/2026/02/Moxi-Applications-Compendium.pdf) Moxi GO II Moxi V Moxi Z 2026 ### Applications Compendium Scientists are concerned with speed, accuracy, and convenience, and those running the lab and industries are concerned with the cost typically associated with high-performing instruments. Our proprietary Coulter Principle-based system delivers on all three accounts, and is therefore a perfect fit for any cell biology benchtop. [Download App Note](https://precisioncellsystems.com/wp-content/uploads/2026/02/Moxi-Applications-Compendium.pdf) [Brochure](https://precisioncellsystems.com/wp-content/uploads/2025/12/Moxi_GO_II_Brochure.pdf) Moxi GO II 2025 ### Brochure - Moxi GO II [Download Brochure](https://precisioncellsystems.com/wp-content/uploads/2025/12/Moxi_GO_II_Brochure.pdf) [Blog](/resources/gmp-cell-therapy-qc-counting-audit-ready/) Moxi GO II 2026 ### GMP Cell-Therapy QC Counting: What Makes a Count Audit-Ready The evergreen guide to what makes a GMP cell-therapy count audit-ready — the hub for the Part 11 and volumetric-vs-image explainers. [Read Blog](/resources/gmp-cell-therapy-qc-counting-audit-ready/) [Blog](/resources/volumetric-vs-image-based-cell-counting-cart-qc/) Moxi GO II 2026 ### Volumetric vs Image-Based Cell Counting for CAR-T QC The method explainer: volumetric vs image-based counting for CAR-T QC, and why the CV gap matters at lot release. [Read Blog](/resources/volumetric-vs-image-based-cell-counting-cart-qc/) [App Note](https://precisioncellsystems.com/wp-content/uploads/2026/02/Moxi-Applications-Note-Unlocking-the-Next-Stage-in-CAR-T-Cellular-Analysis.pdf) Moxi GO II 2026 ### Unlocking the Next Stage in CAR-T Cellular Analysis There are a variety of ways to monitor this process in cell culture, the two most prominent being cell counting via imaging-based and coulter-based cell counting methods and higher-level cellular analysis with fluorophore-tagged antibodies and fluorescent reporters via flow cytometry. While each instrument used to achieve these two things has its advantages and disadvantages, few and far between can do both at once. Out of all your options, no other instrument has the power to do both with the speed, precision, and ease that Precision Cell Systems' Moxi Go II can. In this document, we will take you through how you can unlock the next stage in your cellular analysis process for CAR-T with our instruments. [Download App Note](https://precisioncellsystems.com/wp-content/uploads/2026/02/Moxi-Applications-Note-Unlocking-the-Next-Stage-in-CAR-T-Cellular-Analysis.pdf) [Tech Note](https://precisioncellsystems.com/wp-content/uploads/2025/09/ORFLO-Single-or-Dual-Color-Viability-Staining-Tech-Tip.pdf) Moxi GO II Moxi V 2025 ### Moxi Single or Dual Color Viability Staining Tech Note [Read Tech Note](https://precisioncellsystems.com/wp-content/uploads/2025/09/ORFLO-Single-or-Dual-Color-Viability-Staining-Tech-Tip.pdf) [App Note](https://precisioncellsystems.com/wp-content/uploads/2025/08/Moxi-Car-T-Activation-Monitoring.pdf) Moxi GO II 2025 ### Moxi - CAR-T Activation Monitoring [Download App Note](https://precisioncellsystems.com/wp-content/uploads/2025/08/Moxi-Car-T-Activation-Monitoring.pdf) [Blog](/resources/21-cfr-part-11-cell-counter-requirements/) Moxi GO II 2026 ### What 21 CFR Part 11 Requires of a Cell Counter The compliance explainer: what 21 CFR Part 11 actually demands of a cell counter — audit trail, e-signature, access control, and a Secure Mode. [Read Blog](/resources/21-cfr-part-11-cell-counter-requirements/) [Field Guide](/resources/audit-ready-cell-counting-gmp-guide/) Moxi GO II 2026 ### Audit-Ready Cell Counting for GMP Cell-Therapy QC An educational field guide to the audit-ready framing and the five requirements of a count you can defend. [Read Field Guide](/resources/audit-ready-cell-counting-gmp-guide/) [Blog](/resources/cell-count-is-a-release-assay-cell-therapy/) Moxi GO II 2026 ### In Cell Therapy, Your Cell Count Can Serve as a Release Assay A demand-creation reframe: in GMP cell therapy, the cell count can function as a release assay — and what that shift means for how you count and prove it. [Read Blog](/resources/cell-count-is-a-release-assay-cell-therapy/) [Field Guide](/resources/01-optimization-burden/) Moxi GO II Moxi V 2026 ### The Optimization Burden: Hours Wasted on Viability Protocol Development Every hour spent optimizing viability dye concentrations is an hour not spent on your actual experiments. It's optimized for use - that's the important thing. You don't have to optimize it as a customer. Pre-optimized viability reagents eliminate the titration experiments, the incubation testing, the cell-type-specific protocol development. Why spend time optimizing when validated performance is available from the first use? [Read Field Guide](/resources/01-optimization-burden/) [Field Guide](/resources/02-unknown-product/) Moxi GO II Moxi V 2026 ### The Unknown Product: Most Moxi Users Don't Know This Exists Most of the issue with viability reagents is that most people don't even know they exist. If you're running viability assays on Moxi V or Moxi GO II with generic dyes you optimized yourself, there's a better option you may not have heard about: pre-optimized, ready-to-use viability reagents designed specifically for your instrument. Now you know. [Read Field Guide](/resources/02-unknown-product/)